High frequency of allergic bronchopulmonary aspergillosis in bronchiectasis-COPD overlap

• Main Authors: Tiew, Pei Yee, Lim, Albert Yick Hou, Keir, Holly R., Dicker, Alison J., Mac Aogain, Micheal, Pang, Sze Lei, Low, Teck Boon, Hassan, Tidi Maharani, Poh, Mau Ern, Xu, Huiying, Ong, Thun How, Koh, Mariko Siyue, Abisheganaden, John Arputhan, Tee, Augustine, Chew, Fook Tim, Chalmers, James D., Chotirmall, Sanjay H.
• Format: Article
• Published: Elsevier 2022
• Subjects: QM Human anatomy; QP Physiology; RA Public aspects of medicine
• Online Access: http://eprints.um.edu.my/33610/

BACKGROUND: Allergic bronchopulmonary aspergillosis (ABPA) is associated with frequent exacerbations and poor outcomes in chronic respiratory disease, but remains under-diagnosed. The role of fungal sensitization in bronchiectasis-COPD overlap (BCO) is unknown. RESEARCH QUESTION: What is the occurrence and clinical relevance of Aspergillus sensitization and ABPA in BCO when compared with individuals with COPD or bronchiectasis without overlap? STUDY DESIGN: Prospective, observational, cross-sectional study. METHODS: We prospectively recruited 280 patients during periods of clinical stability with bronchiectasis (n = 183), COPD (n = 50), and BCO (n = 47) from six hospitals across three countries (Singapore, Malaysia, and Scotland). We assessed sensitization responses (as specific IgE) to a panel of recombinant Aspergillus fumigatus allergens and the occurrence of ABPA in relationship to clinical outcomes. RESULTS: Individuals with BCO show an increased frequency and clinical severity of ABPA compared with those with COPD and bronchiectasis without overlap. BCO-associated ABPA is associated with more severe disease, higher exacerbation rates, and lower lung function when compared with ABPA occurring in the absence of overlap. BCO with a severe bronchiectasis severity index (BSI; > 9) is associated significantly with the occurrence of ABPA that is unrelated to underlying COPD severity. CONCLUSIONS: BCO demonstrates a high frequency of ABPA that is associated with a severe BSI (> 9) and poor clinical outcomes. Clinicians should maintain a high index of suspicion for the potential development of ABPA in patients with BCO with high BSI.